Nurix Therapeutics (NRIX) Liabilities and Shareholders Equity (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $535.5 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 9.47% year-over-year to $535.5 million in Q2 2026; TTM through May 2026 was $2.4 billion, a 0.3% change from a year earlier, with the FY2025 full-year figure at $688.1 million, up 2.81% from the prior year.
• Liabilities and Shareholders Equity for Q2 2026 stood at $535.5 million, down from $636.1 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for NRIX reached as high as $688.1 million in Q4 2025 and fell as low as $308.2 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $482.7 million across 5 years, with a median of $485.2 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 32.9% in 2023 and soared 96.7% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $416.8 million in 2022, then declined by 14.68% to $355.6 million in 2023, then jumped by 88.23% to $669.3 million in 2024, then gained by 2.81% to $688.1 million in 2025, then decreased by 22.18% to $535.5 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $535.5 million in Q2 2026, $636.1 million in Q1 2026, and $688.1 million in Q4 2025.